RxDoctor Payments Data

Patrick Oconnell, MD

Family Medicine · Tehachapi, CANPI 1861503187

Payments from drug & device makers

$789in general payments, 2019–2025

Across 25 payments — averaging $31.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hikma Pharmaceuticals USA$344
  • GSK$96
  • Exact Sciences$57
  • Acadia Pharmaceuticals Inc$55
  • Boehringer Ingelheim$52
  • Lilly USA, LLC$36
  • plus $151 from 8 others

What the payments were for

  • Consulting fees$34444%
  • Food & beverage$44656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$789 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$87,515
Medicare patients
245
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$61,800
Trelegy ElliptaFluticasone/Umeclidin/Vilanter64$48,717
JardianceEmpagliflozin35$38,587
OzempicSemaglutide34$31,531
XareltoRivaroxaban25$24,284
TrulicityDulaglutide14$23,750
JanuviaSitagliptin Phosphate22$20,344
Xigduo XrDapaglifloz Propaned/Metformin12$12,704
FarxigaDapagliflozin Propanediol16$10,001
Victoza 3-PakLiraglutide12$9,545
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen324$7,570
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,043
BrilintaTicagrelor11$4,876
Albuterol Sulfate HfaAlbuterol Sulfate163$4,672
Fluticasone Propionate HfaFluticasone Propionate11$3,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$96$48,71764 claims
Boehringer IngelheimJardiance$52$38,58735 claims
Novo NordiskOzempic$15$31,53134 claims
Lilly USA, LLCTrulicity$36$23,75014 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Tehachapi

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →